Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies
- PMID: 28589744
- PMCID: PMC6041929
- DOI: 10.1177/1534735417712007
Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies
Abstract
Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients' vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), Pfor linear trend < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively. There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.
Keywords: breast cancer; dose-response meta-analysis; dose-response relationship; meta-analysis; overall survival; vitamin D.
Conflict of interest statement
Figures



Similar articles
-
Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies.Medicine (Baltimore). 2013 May;92(3):123-131. doi: 10.1097/MD.0b013e3182943bc2. Medicine (Baltimore). 2013. PMID: 23625163 Free PMC article. Review.
-
Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors?Int J Cancer. 2014 Jun 15;134(12):2972-83. doi: 10.1002/ijc.28628. Epub 2013 Dec 7. Int J Cancer. 2014. PMID: 24272459
-
Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study.Breast Cancer Res. 2011 Jul 26;13(4):R74. doi: 10.1186/bcr2920. Breast Cancer Res. 2011. PMID: 21791049 Free PMC article.
-
Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study.Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):900-908. doi: 10.1158/1055-9965.EPI-18-1155. Epub 2019 Mar 6. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 30842127
-
Circulating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis.Cancer Causes Control. 2015 Dec;26(12):1719-28. doi: 10.1007/s10552-015-0665-6. Epub 2015 Sep 10. Cancer Causes Control. 2015. PMID: 26358829 Review.
Cited by
-
Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women.Cancers (Basel). 2017 Oct 24;9(10):144. doi: 10.3390/cancers9100144. Cancers (Basel). 2017. PMID: 29064397 Free PMC article.
-
Vitamin D regulation of energy metabolism in cancer.Br J Pharmacol. 2022 Jun;179(12):2890-2905. doi: 10.1111/bph.15424. Epub 2021 Apr 8. Br J Pharmacol. 2022. PMID: 33651382 Free PMC article. Review.
-
Vitamin D and Hypoxia: Points of Interplay in Cancer.Cancers (Basel). 2022 Mar 31;14(7):1791. doi: 10.3390/cancers14071791. Cancers (Basel). 2022. PMID: 35406562 Free PMC article. Review.
-
Serum Levels of 25-Hydroxyvitamin D at Diagnosis Are Not Associated with Overall Survival in Esophageal Adenocarcinoma.Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1379-1387. doi: 10.1158/1055-9965.EPI-18-1190. Epub 2019 Jun 11. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31186263 Free PMC article.
-
Impact of Vitamin D Levels on Progression-Free Survival and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Cancers (Basel). 2024 Dec 17;16(24):4206. doi: 10.3390/cancers16244206. Cancers (Basel). 2024. PMID: 39766105 Free PMC article. Review.
References
-
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. - PubMed
-
- Vrieling A, Seibold P, Johnson TS, et al. Circulating 25-hydroxyvitamin D and postmenopausal breast cancer survival: influence of tumor characteristics and lifestyle factors? Int J Cancer. 2014;134:2972-2983. - PubMed
-
- Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27:3757-3763. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical